Barclays analyst Matt Miksic raised the firm’s price target on Tandem Diabetes (TNDM) to $56 from $55 and keeps an Overweight rating on the shares. The company’s new strategy and guidance reflects “strong” underlying double-digit growth in 2026, with potential for upside, the analyst tells investors in a research note.
Meet Samuel – Your Personal Investing Prophet
- Start a conversation with TipRanks’ trusted, data-backed investment intelligence
- Ask Samuel about stocks, your portfolio, or the market and get instant, personalized insights in seconds
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on TNDM:
- Tandem Diabetes Care Earnings Call Signals Strategic Shift
- Midday Fly By: Supreme Court strikes down Trump tariffs
- Walmart downgraded, Etsy upgraded: Wall Street’s top analyst calls
- Tandem Diabetes price target raised to $22 from $21 at Mizuho
- Tandem Diabetes price target raised to $22 from $20 at Stifel